BET and BAZ2A/B domain inhibitors are currently being evaluated at different stages of clinical trials for treating a variety of different cancer types (https://clinicaltrials.gov/; Identifiers: NCT05111561, NCT05053971, NCT05301972, NCT04910152, NCT04471974). Here, BAZ2A is linked to cancer.